Numab Therapeutics

J&J Acquires Numab's Eczema Drug in $1.25B Deal

Johnson & Johnson is acquiring Yellow Jersey Therapeutics from Numab Therapeutics for $1.25 billion in cash, marking its second acquisition in the immunology and inflammation (I&I) sector.